Aegerion Pharmaceuticals Enterprise Value:
1.643B for May 17, 2013Aegerion Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 1.643B |
| May 16, 2013 | 1.647B |
| May 15, 2013 | 1.223B |
| May 14, 2013 | 1.241B |
| May 13, 2013 | 1.199B |
| May 10, 2013 | 1.197B |
| May 9, 2013 | 1.138B |
| May 8, 2013 | 1.101B |
| May 7, 2013 | 1.106B |
| May 6, 2013 | 1.099B |
| May 3, 2013 | 1.103B |
| May 2, 2013 | 1.131B |
| May 1, 2013 | 1.127B |
| April 30, 2013 | 1.081B |
| April 29, 2013 | 1.048B |
| April 26, 2013 | 954.59M |
| April 25, 2013 | 971.59M |
| April 24, 2013 | 981.10M |
| April 23, 2013 | 1.040B |
| April 22, 2013 | 1.030B |
| April 19, 2013 | 1.062B |
| April 18, 2013 | 1.022B |
| April 17, 2013 | 993.77M |
| April 16, 2013 | 985.42M |
| April 15, 2013 | 1.004B |
| April 12, 2013 | 1.016B |
| April 11, 2013 | 983.40M |
| April 10, 2013 | 1.021B |
| April 9, 2013 | 987.72M |
| April 8, 2013 | 992.91M |
| April 5, 2013 | 983.69M |
| April 4, 2013 | 973.32M |
| April 3, 2013 | 971.59M |
| April 2, 2013 | 1.000B |
| April 1, 2013 | 993.77M |
| March 28, 2013 | 1.091B |
| March 27, 2013 | 1.030B |
| March 26, 2013 | 1.037B |
| March 25, 2013 | 1.024B |
| March 22, 2013 | 1.032B |
| March 21, 2013 | 1.030B |
| March 20, 2013 | 1.042B |
| March 19, 2013 | 1.032B |
| March 18, 2013 | 1.046B |
| March 15, 2013 | 1.013B |
| March 14, 2013 | 1.006B |
| March 13, 2013 | 995.00M |
| March 12, 2013 | 997.02M |
| March 11, 2013 | 998.46M |
| March 8, 2013 | 991.55M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
AEGR Enterprise Value Benchmarks
| Companies | |
|---|---|
| Isis Pharmaceuticals | 1.928B |
| Sanofi | 156.90B |
| Keryx Biopharmaceuticals | 642.04M |
AEGR Enterprise Value Rankings
| Overall |
78th percentile 1697 of 8007 |
| Sector |
80th percentile 135 of 685 in Healthcare |
| Industry |
76th percentile 16 of 68 in Drug Manufacturers - Specialty & Generic |
AEGR Enterprise Value Range, Past 5 Years
| Minimum | 163.19M | Jan 28 2011 |
| Maximum | 1.647B | May 16 2013 |
| Average | 358.46M |
